Breast cancer drug cuts risk of most common form returning by 25%

Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly

Thousands of women with the world's most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.

More than 2 million people globally are diagnosed each year with the disease, which is the world's most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.